Lung Cancer Screening Guide vs NoduleRisk

Download includes a free trial; continued use requires a 6‑ or 12‑month auto‑renewing subscription. Lung Cancer Screening Guide is a clinical decision‑support tool built around ACR Lung‑RADS v2022, including the new “S” modifier for clinically significant incidental findings. The app delivers step‑by‑step guidance at the point of care, streamlining lung‑nodule categorization and follow‑up so you can apply standardized recommendations with clarity and consistency—whether you practice in radiology, pulmonology, or primary care. --- Key Features (unlocked after the free trial with an active subscription) ACR Lung‑RADS v2022 Integration • Full, in‑app access to every Lung‑RADS category (0–4X) plus the “S” modifier, with concise management instructions drawn directly from the guidelines. Dynamic Lung‑RADS Card • A single, color‑coded card that updates your Lung‑RADS score in real time as you enter screening round, nodule morphology, size, and growth—making classification fast. S Modifier Integration • Toggle clinically significant findings across organ systems (e.g., coronary calcium, thyroid nodule, liver lesion) and instantly receive tailored, ACR‑based follow‑up recommendations sourced from the ACR Incidental Findings White Papers. Comprehensive Nodule Insights • Practical guidance on measuring nodules, stepped management pathways, etc. Self-Assessment Mode • Expert-curated self-assessment question packs. Brock (Full Model) Calculator • Calculate a CT-detected nodule’s 2–4 year malignancy risk. Enhanced Readability • Dark‑mode support, dynamic text sizing, and a distraction‑free interface optimized for hectic reading environments. Offline Access • All guideline logic run on‑device—no login or server needed. Medical Disclaimer: This app is for informational purposes only and is not a substitute for professional medical advice. In addition to using this app, always consult a qualified healthcare provider for diagnosis and treatment decisions. SUBSCRIPTION OPTIONS ¹ • 6‑Month subscription (free trial available) | Price displayed in‑app; may vary by region • 12‑Month subscription (free trial available) | Price displayed in‑app; may vary by region We strive to incorporate any updates to ACR Lung‑RADS or S Modifier guidance within 30 days of publication and plan to add new self‑assessment question packs every six months. Future feature additions and update frequency may change without notice. ¹ Payment & Renewal – Payment is charged to your Apple ID at confirmation. Subscriptions renew automatically unless auto-renew is turned off at least 24 hours before the end of the current period. Manage or cancel anytime in Settings ▸ Apple ID ▸ Subscriptions. Note: If you switch plans or re-subscribe during the free trial, the remaining trial time is lost and you will be charged immediately. Privacy Policy: https://radiologiq.squarespace.com/privacy Terms of Use (EULA): https://www.apple.com/legal/internet-services/itunes/dev/stdeula/

NoduleRisk is a clinical decision support tool for physicians evaluating pulmonary nodule malignancy risk. It computes probability estimates and management guidance across five validated models simultaneously. MODELS INCLUDED • Mayo Clinic (ACCP) — logistic regression model for incidentally detected nodules • Brock (BTS/PanCan) — recommended for screening populations; validated in the Pan-Canadian Lung Cancer Screening Study • Herder (BTS) — incorporates FDG-PET/CT uptake when available • BIMC (Bayesian) — Bayesian likelihood ratio model with adjustable prior probability; displays individual likelihood ratio contributions • Fleischner 2017 — guideline-based follow-up recommendations with automatic risk stratification FEATURES • Multi-nodule evaluation (up to 6 nodules per patient) • Volume doubling time calculation from serial CT measurements • Risk-stratified management recommendations for each model • Applicability warnings when inputs are outside model validation ranges • Clinical context adjustments for screening and biopsy-referred populations • Fully offline — no data is transmitted or stored IMPORTANT NoduleRisk is intended for use by qualified clinicians as a decision support aid only. Results must be interpreted in the context of the full clinical picture and do not substitute for institutional guidelines, multidisciplinary team discussion, or clinical judgment.